reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
| Common synonyms | GIP/GLP-1 dual agonist; LY3298176 | Development codes appear in earlier literature |
| Purity specification | Usually 95% or higher by HPLC area | Research-grade lots are often 98% or higher |
| Solution storage | 2–8 °C, protected from light | Short term; avoid repeated freeze-thaw cycles |
| Dry powder storage | −20 °C or below, desiccated | Protected from moisture and light |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
=== Pair potentials versus many-body potentials === The potential functions representing the non-bonded energy are formulated as a sum over interactions between the particles of the system. The simplest choice, employed in many popular force fields, is the "pair potential", in which the total potential energy can be calculated from the sum of energy contributions between pairs of atoms. Therefore, these force fields are also called "additive force fields". An example of such a pair potential is the non-bonded Lennard-Jones potential (also termed the 6–12 potential), used for calculating van der Waals forces.
The two substrates of this enzyme are (5β)-pregnan-21-ol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (5β)-pregnan-21-al, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 21-hydroxysteroid:NAD+ 21-oxidoreductase. This enzyme is also called 21-hydroxysteroid dehydrogenase (NAD+).
=== 2000–2011: Established actor and diversification === In 2000, Carrey reteamed with the Farrelly brothers, who had previously directed him in Dumb and Dumber, for the black comedy film Me, Myself & Irene, a film that received mixed reviews but enjoyed box office success. Carrey played the role of state trooper Charlie Baileygates, who has multiple personalities and romances a woman portrayed by Renée Zellweger. That same year, Carrey starred in the second highest-grossing Christmas film of all time, How the Grinch Stole Christmas, playing the title character, for which he received both praise and criticism from critics alongside a Golden Globe nomination. For his next feature film, Carrey starred opposite Jennifer Aniston and Morgan Freeman in Tom Shadyac's international hit comedy Bruce Almighty (2003). Carrey played a television newsman who unexpectedly receives God's omnipotent abilities when the deity decides to take a vacation. The film received mixed reviews upon release but still became a financial success, earning over $484 million worldwide, and going on to become the seventeenth highest-grossing live action comedy of all time. In 2004, Carrey starred in Eternal Sunshine of the Spotless Mind. The film received critical acclaim upon release. Critics highly praised Carrey's portrayal of Joel Barish, in addition to the performance of his co-star Kate Winslet, who was nominated for an Oscar.
17 May – Plaid Cymru ends its co-operation deal with Labour in Wales following concerns about a donation of £200,000 to First Minister Vaughan Gething's leadership campaign by a company owned by a businessman twice convicted of environmental offences. South Wales Police and the Senedd Commission for Standards launch investigations into allegations that Conservative MS Laura Anne Jones made false expenses claims. 18 May – Chris Heaton-Harris, the secretary of state for Northern Ireland, confirms he will be standing down from Parliament at the next general election. 20 May – Ofcom says it is considering imposing a statutory sanction against GB News after concluding its programme People's Forum: The Prime Minister, a Q&A session with prime minister Rishi Sunak that aired in February, broke impartiality rules. The Stormont Assembly endorses a Legislative Consent Motion to extend the Pet Abduction Bill, introduced at Westminster, to Northern Ireland, making the abduction of cats and dogs a criminal offence. 21 May – The High Court rules that UK government plans to extend police powers over protests are unlawful. Stormont votes in favour of adopting Westminster's Tobacco and Vapes Bill that will gradually phase in a smoking ban from 2027. 22 May – Rishi Sunak announces that a general election will be held on 4 July. Craig Mackinlay, MP for Thanet South, returns to the House of Commons following a long absence after contracting sepsis, an illness that required him to undergo a quadruple amputation, and receives a rare standing ovation from colleagues.
Sources: en.wikipedia.org
In 1942, Hugh DeHaven published the classic Mechanical analysis of survival in falls from heights of fifty to one hundred and fifty feet. In 1947, the American Tucker was built with the world's first padded dashboard. It also came with middle headlight that turned with the steering wheel, a front steel bulkhead, and a front safety chamber. In 1949, SAAB incorporated aircraft safety thinking into automobiles making the Saab 92 the first production SAAB car with a safety cage. Also in 1949, the Chrysler Imperial Crown was the first car to come with standard disc brakes.
Single nucleotide polymorphism annotation (SNP annotation) is the process of predicting the effect or function of an individual SNP using SNP annotation tools. In SNP annotation the biological information is extracted, collected and displayed in a clear form amenable to query. SNP functional annotation is typically performed based on the available information on nucleic acid and protein sequences.
The main use for 4-aminosalicylic acid is for the treatment of tuberculosis infections. In the United States, 4-aminosalicylic acid is indicated for the treatment of tuberculosis in combination with other active agents. In the European Union, it is used in combination with other medicines to treat adults and children from 28 days of age who have multi-drug resistant tuberculosis when combinations without this medicine cannot be used, either because the disease is resistant to them or because of their side effects.
Sources: en.wikipedia.org
Because of the great insolubility of thorium dioxide, thorium does not usually spread quickly through the environment when released. The Th4+ ion is soluble, especially in acidic soils, and in such conditions the thorium concentration can be higher.
A potentially controversial method of producing biopharmaceuticals involves transgenic organisms, particularly plants and animals that have been genetically modified to produce drugs. This production is a significant risk for its investor due to production failure or scrutiny from regulatory bodies based on perceived risks and ethical issues. Biopharmaceutical crops also represent a risk of cross-contamination with non-engineered crops, or crops engineered for non-medical purposes. One potential approach to this technology is the creation of a transgenic mammal that can produce the biopharmaceutical in its milk, blood, or urine. Once an animal is produced, typically using the pronuclear microinjection method, it becomes efficacious to use cloning technology to create additional offspring that carry the favorable modified genome. The first such drug manufactured from the milk of a genetically modified goat was ATryn, but marketing permission was blocked by the European Medicines Agency in February 2006. This decision was reversed in June 2006 and approval was given August 2006.
He noted their unusual physiological characteristics. On 7 June, Humboldt, Bonpland, and Sotto began the final 300 miles of their journey. As the river widened, the population grew more diverse. They reached Angostura, now Ciudad Bolivar, on 13 June, completing a pioneering exploration of 1,500 miles between the Orinoco and Amazon basins. The expedition measured positions of more than 50 locations, collected magnetic data, and amassed 12,000 plant specimens, many new to science. Humboldt credited Bonpland’s energy and courage. The climate damaged a significant portion of their botanical collection. Shortly after arrival in Angostura, Humboldt, Bonpland, and a servant became seriously ill, likely with typhoid. Humboldt recovered quickly, but Bonpland’s illness was severe and slow to resolve. After a month, Bonpland was fit enough for the journey across the Llanos to the coast. Their return was delayed by a privateer, but British naval intervention rescued them. By late August 1800, they reached Cumana, concluding the first phase of their South American expedition after nearly a year away.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the usual approach, frequently combined with mass spectrometry for identity. Purity is reported as the area percentage of the main peak. Related impurities eluting near the main peak are usually summed and reported separately.
Removing water slows hydrolysis and limits aggregation, so dry powder retains its quality attributes longer than a solution. Suppliers define a shelf life and retest date for the dried form at specified temperatures. Once dissolved, the practical working lifetime shortens considerably.
It generally lists appearance, identity by mass, purity by chromatography, water or residual solvent content, and the methods used. Storage recommendations and a retest date are commonly included. Values are reported against a supplier specification rather than a single universal standard.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.